Harvard Study Advances Tattoo Removal

Brooklyn, NY (PRWEB) August 31, 2011

Q-switched lasers are typically used for tattoo removal, but the devices are ill-equipped for the treatment of some conditions, including allergic tattoo reactions. Though long considered the gold standard, these lasers can cause pain and discomfort, are unable to remove some color spectrums such as yellow, and non-tattooed areas of the skin are often exposed to laser light, as the beam lacks precision. Over the last 10 years, just two different types of lasers have been employed for tattoo removal, with many limitations. Ablative fractional resurfacing (AFR) offers a solution to these shortcomings.

The Sciton? Fractionated Erbium laser is used in conjunction with a traditional laser, and utilizes a computer-controlled scanner so that only the area being treated is actually exposed to laser energy. In addition to tattoo removal and the treatment of allergic tattoo reactions, the laser can be used for combination treatments, such as scar removal or scar repair. All colors, including hard-to-treat colors, can be removed with the Sciton? Fractionated Erbium laser, in less time than with traditional lasers. This is possible because the laser penetrates deep into the skin to more effectively break up the ink pigmentation. Once the ink has been exposed to the laser energy and broken up, it is naturally absorbed into the body. As the ink becomes less concentrated, it begins to fade, eventually dissolving altogether. The Sciton? Fractionated Erbium laser is so effective that the number of treatment sessions required can be markedly reduced, saving the patient time and money.

In a study conducted by Harvard University, published in the Journal of the American Academy of Dermatology (JAAD) in June 2011, two patients were treated with the AFR Sciton? Fractionated Erbium laser. The first patient, a male aged 52, suffered an allergic reaction from a portion of a multi-colored tattoo on his upper extremity. The second patient was a 31-year-old woman with a red and black tattoo on her lower extremity. After a series of treatments with the AFR, both patients experienced a substantial or complete resolution of symptoms, and the tattoo ink was significantly reduced or completely removed. The Harvard study concluded that AFR treatment ? such as that offered by the Sciton? Fractionated Erbium laser ? was safe and effective for the removal of allergic tattoos.

As reported in the New York Times, a recent report by the Food and Drug Administration (FDA) estimates that nearly 45 million Americans have tattoos; tellingly, nearly 17 percent of those with tattoos, or some 7 million people, regret their decision. Tattoo removal is becoming increasingly popular each year. Dr. Morris Westfried of New York City recognizes the need within his community for this service and is now using this standardized approach.

Call (718) 837-9004 to schedule an appointment with Morris Westfried. MD, an expert tattoo removal and laser treatment specialist.

For further information, visit http://www.tattoos-removed.com.

###

Can Beauty be Found in a Bottle? New Study Shows it Can

Newport Beach CA (PRWEB) June 23, 2011

BioCell Technology LLC announces the completion of the first human skin study of BioCell Collagen II? in women who have undergone natural and UV-intensified aging processes. In broad brushstrokes, this study has demonstrated the safety and significant efficacy of BioCell Collagen II? in improving a variety of aging-associated facial effects measured both qualitatively and quantitatively.

BioCell Collagen II? is a naturally-occurring matrix containing hydrolyzed collagen and highly-bioavailable hyaluronic acid. It had been strongly implicated as a healthy-aging ingredient that promotes both joint and skin health, and specifically causing the ?beauty from the inside? effects that have traditionally been achieved with external or invasive wrinkle-reducing treatments. The outcome of previous studies demonstrated an excellent safety profile and efficacy in bioavailability, increased levels of hyaluronic acid, and inhibition of hyaluronidase, providing more turgid, hydrated, and supple skin. BioCell Collagen II? has also been shown in human clinical trials to reduce joint discomfort and stiffness as much as 40% in eight weeks.

Encouraged by the consistently favorable outcome of the earlier studies, BioCell Technology recently completed a study investigating the effects of BioCell Collagen II? on diverse parameters relevant to aged appearance of the facial skin. These parameters included dryness, wrinkles, deep lines and collagen content. This study on skin aging has proven that BioCell Collagen II? is indeed an essential "nutricosmetic" ingredient that promotes healthy aging. Its multi-layered mechanisms of action have been shown to synergistically antagonize the skin aging process and promote younger-looking appearance with better hydration, higher collagen content, reduced wrinkle counts and shallower line depth. As a result, a majority of the study participants experienced a remarkable improvement in skin texture, together with hydration, reduced scaling, and improved blood microcirculation.

Dr. Joosang Park, principal investigator of the research team, says that the details of the study will be published in the near future. Dr. Park who conducted research at Harvard Medical School for many years applies the rigorous standards of pharmaceutical research and practices to nutritional ingredients. "The extraordinary fact about this study is that the subjects took BioCell Collagen II? orally for skin beauty;? said Dr. Park, ?this was not a topical study. It means that BioCell Collagen II? is not only a true nutraceutical, but that it can offer less wrinkles, increased collagen, and supple, hydrated skin by working from the inside-out.? Dr. Park also stated, ?This and earlier studies demonstrate that BioCell Collagen II can support the skin dermis collagen network containing collagen types I and III as well as collagen type II in the joint. I?m encouraged about these findings and that it adds to the portfolio of research that makes BioCell Collagen II? a true nutricosmetic substantiated by multiple human studies.?

Ms. Asma Ishaq, vice president of marketing and Dr. Park will present the top-line data and discuss the research at the upcoming Nutricosmetic Summit 2011 in Las Vegas. The conference focuses on the emerging and rapidly growing nutricosmetic segment of the dietary supplement industry, which is a direct result of a growing acceptance of younger people investing in anti-aging measures and more so by 11,000 baby boomers turning 50 every day. This trend will continue for the next 10 years, and by 2012, 50 percent of the entire US population will be over 50.

Leading this category with science, BioCell Technology also earns praise from industry experts. ?It?s important to see new science emerging in this area, specifically with ingested products, and we applaud companies such as BioCell that are leading this charge?, notes Len Monheit, Executive Director of the New Hope Supply Network and hosts of the Nutricosmetic Summit. ?Moreover, we are glad that the Summit is the place where this advance is to be presented, and the commitment that BioCell has made in working with our Supply Network to validate and build this category globally.?

About BioCell Collagen II:

BioCell Collagen II? is an innovative dietary ingredient marketed as a healthy aging nutritional supplement that promotes both healthy joints and more youthful-looking skin. It is unique in that it is a naturally-occurring matrix whose three major constituents, collagen type II, chondroitin sulfate, and hyaluronic acid, are reduced to highly-bioavailable, very low molecular weight forms due to its patented hydrolysis process. Made exclusively from articular sternum cartilage, its composition is similar to that of human articular joint cartilage.

About BioCell Technology:

Founded in 1997, BioCell Technology, LLC is the exclusive supplier of BioCell Collagen II? and owns the exclusive rights to market it under US Patents 6,025,327, 6,323,319, 6,780,841 and 7,091,180. The product logo is registered and is available for display on the labels of BioCell Technology, LLC's private label clients for marketing under their own brand names or formulas. For more information on BioCell Collagen II, please contact BioCell Technology, LLC at (714) 632-1231 or visit http://www.biocelltechnology.com.

Contact:

Suhail Ishaq

President

BioCell Technology LLC

Tel. 714-632-1231

Email: suhail(at)biocelltechnology(dot)com

# # #

Swedish Study Adds Further Weight to Eludril and Elgydium Gum Disease Warnings

Bournemouth, Dorset (PRWEB) December 14, 2011

New research from Sweden into gum disease adds further weight to concerns over its links with more serious medical conditions, warn the experts at Eludril and Elgydium.

Bleeding gums ? which some people foolishly dismiss as a common occurrence ? have been identified as an important health warning sign in the new Swedish study.

People with the highest incidence of bleeding gums are more likely to suffer from a stroke than those with the lowest incidence, said the Centre for Research and Development of the County Council of G?vleborg, Sweden.

Its study of around 8,000 people has produced a series of potential health risk indicators:

????People with fewer than 21 teeth had a 69 per cent higher risk of heart attack compared with those with the most teeth.
????Higher numbers of deep periodontal pockets (gum infection around the base of the tooth) had a 53 per cent higher risk of heart attack compared with those with the fewest pockets.
????People with the least teeth had an increased risk of congestive heart failure compared with those with the most.

The Swedish study echoes similar research presented to the American Heart Association which showed that people who have their teeth cleaned by dentists or hygienists at least every 12 months are 25 per cent less likely to suffer a heart attack.

Both sets of research back up oral health care advice given by the manufacturers of the medicinal products Eludril mouthwash and Elgydium toothpaste.

A spokesman for Elgydium and Eludril said: ?The new Swedish study is yet more evidence of the correlation between gum disease and more serious medical conditions.

?Increasing numbers of studies are pointing to the link, highlighting the importance of adopting a good oral health care regime and sticking to it.?

During the last two years there have been at least 146 clinical trials relating to gum disease in the United States alone with 72 more in Europe, 26 in the Middle East, 22 in South America plus several dozen more in the rest of the world.

The correlation between gum disease and cardiac conditions has been suggested for a number of years and latest research continues to back this up.

Lack of attention to basic oral health care, such as brushing and flossing, results in plaque which then leads to bacteria and gum disease.

Even seemingly minor gum disease symptoms could be an early indication of more serious medical problems later in life.

Typical early signs of gum disease include swollen gums, a prelude to more pressing symptoms.

Sore gums should be sufficient reason to go to the dentist and tackle the problem quickly before it worsens but some people suffer in silence instead.

Ignoring these early stages can result in receding gums which not only jeopardises the teeth ? it leaves the body vulnerable to more serious medical problems caused by bacteria and infections.

Using a medicinal toothpaste such as Elgydium every day helps to ward off plaque and the signs of gum disease.

Elgydium contains the active ingredient chlorhexidine, widely regarded by dentists and hygienists around the world as the leading gingivitis treatment.

Tried and tested chlorhexidine ? which has been used since the 1980s ? is also one of the active ingredients in Eludril, a leading medicinal mouthwash developed to help combat gum disease.

Eludril is a menthol-flavoured mouthwash that is recommended as a short-term treatment for gum disease. One rinse can keep working for up to 12 hours.

Dental professionals recommend a 15ml dosage (for adults and children aged over 6) diluted with lukewarm water using the measuring cup provided.

Discover how Elgydium and Eludril can help to stop gum disease. Contact Nikki Pounds at Ceuta Healthcare on +44 (0)1202 780558.

Notes For Editors

Eludril and Elgydium are represented in the UK by:

Ceuta Healthcare Ltd

Hill House

41 Richmond Hill

Bournemouth

Dorset

BH2 6HS

Tel: +44 (0)1202 780558

Eludril Mouthwash is an antibacterial and analgesic solution which can be used to manage a number of oral health problems.

Its main use is to treat and prevent dental plaque formation and gum disease (gingivitis, also known as periodontitis) by preventing the build-up of bacteria.

Eludril Mouthwash can also be used to maintain oral hygiene in situations where tooth brushing is difficult, for instance, following oral surgery or in physically or mentally handicapped patients.

Eludril can also be used as a disinfectant for the cleansing of removable dentures and in the management of common mouth ulcers and oral candidiasis infections (fungus infections).

Elgydium Anti-Plaque toothpaste is specially formulated for sensitive gums and helps to prevent dental plaque and tartar build-up, the major causes of tooth decay and gum disease.

Elgydium Whitening, Sensitive and Decay Protection are also available as part of the Elgydium range of toothpastes.

###

Study Shows Women Battling Breast Cancer Now Have New Option for Reconstruction at the Same Time as Mastectomy

(PRWEB) August 02, 2011

Cassileth One-Stage Breast Reconstruction offers customized, natural looking breasts immediately after one surgery.

For the first time, women can now wake up from a double mastectomy with customized breasts with virtually no scars. This new procedure was reviewed in a recently released study entitled ?One-Stage Immediate Breast Reconstruction With Implants? published in the "Annals of Plastic Surgery."

One in eight women will develop breast cancer in their lifetime. More women are opting for mastectomy with reconstruction. In 2010 more than 250,000 new cases of breast cancer were diagnosed in America. Last year, 93,083 reconstructive surgeries were performed. That?s an eight percent rise from the 78,832 in 2000. The majority of these women are choosing reconstruction with implants.

There was a time when women had to wake up from the mastectomy enduring the trauma of having no breasts. Then in ?90s a two-stage option of tissue-expander reconstruction became available. Today immediate implants at the time of reconstruction have become an option with limited use. The current immediate implant option offers women up to a 200-gram breast size reconstruction. So if a woman is a 750- gram breast size, she is forced to go smaller with the current one-stage procedure. The alternative is the painful process of the two-stage tissue expander procedure that involves expanding the skin with a temporary implant placed during the mastectomy followed by the additional fear and anxiety that a woman endures for the second surgery to place the permanent implant ?until now.

Dr. Lisa Cassileth, a reconstruction surgeon specialist in Beverly Hills, uses acellular dermal matrix (healthy donor tissue) to build an internal customized bra that can hold a silicone implant of any size. Dr. Cassileth sculpts the two-dimensional sheets of tissue into a three-dimensional bra-like shape that mirror the natural shape of the breast and then she tailors the tissue to the woman?s body-type, size and measurements. This eliminates the flat bump-like appearance that characterizes the current immediate implant approach. During the mastectomy, she works side-by-side with the oncologist to reconstruct the breasts and make tiny incisions. Post surgery, she conceals the incisions with a nipple reconstruction to erase any reminders of the mastectomy.

Dr. Cassileth conducted the study on 43 women and a total of 78 breasts. According to the study based on the judgments of patients and independent observers, this one-stage immediate reconstruction is superior in aesthetic outcome. Dr. Cassileth?s patients are even trading their older models, for newer, bigger, perkier breasts that they report are better looking than their own. This new option minimizes recovery time, costs, discomfort and psychological adjustment that accompany the current two-stage tissue expander procedure.

Survey studies report that an important factor in the choice for mastectomy is fear of recurrence. Studies also reported that the choice for conservation of the breast was due to a concern about the cosmetic outcome. This latest One-Stage Immediate Breast Reconstruction provides women for the first time with a solution to prevent breast cancer recurrence without sacrificing the aesthetics.

We have two patients who could really help tell this story. Alice Crisci is 31. She is young, frank and honest in sharing her story about dealing with the repercussions of breast cancer and her new set of breasts. Mary Beth De Lucia is 52 and shares her story of finding Dr. Cassileth to do the one-stage immediate reconstruction instead of having to endure the two-stage expanders to achieve her natural breast-size after the mastectomy.????

###